FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Merus NV's Free Cash Flow for the
three
months ended in Mar. 2024 was $-44.45 Mil. Merus NV's Revenue for the
three
months ended in Mar. 2024 was $7.89 Mil. Therefore, Merus NV's FCF Margin % for the quarter that ended in Mar. 2024 was -563.46%.
The historical rank and industry rank for Merus NV's FCF Margin % or its related term are showing as below:
MRUS'
s FCF Margin % Range Over the Past 10 Years
Min: -2335.73 Med: -301.9 Max: -123.19
Current: -391.99
During the past 12 years, the highest FCF Margin % of Merus NV was -123.19%. The lowest was -2335.73%. And the median was -301.90%.
MRUS's FCF Margin % is ranked worse than 63.13% of 1047
companies
in the Biotechnology industry
Industry Median: -145.04
vs MRUS: -391.99
Merus NV FCF Margin % Historical Data
The historical data trend for Merus NV's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Merus NV's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Merus NV's FCF Margin % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Merus NV's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Merus NV's FCF Margin % falls into.
Merus NV FCF Margin % Calculation
FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.
Merus NV's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Merus NV FCF Margin % Related Terms
Thank you for viewing the detailed overview of Merus NV's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics. Merus only reportable segment comprising the discovery and development of innovative bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MRUS has been successfully added to your 